TransMedics Group Inc (TMDX)

Return on total capital

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Earnings before interest and tax (EBIT) (ttm)	US$ in thousands	31,455	-803	-14,217	-28,727	-38,109	-15,318	-24,157	-31,437	-35,986	-42,167	-42,290	-39,428	-33,996	-26,881	-24,874	-26,384	-29,182	-31,814	-31,658	-29,603
Long-term debt	US$ in thousands	508,531	507,751	506,976	506,204	505,434	504,669	58,802	58,696	58,540	35,500	35,334	35,197	35,058	34,921	34,787	34,657	34,525	34,395	34,269	34,146
Total stockholders’ equity	US$ in thousands	209,920	189,894	159,471	137,202	126,460	145,213	192,625	187,375	187,857	50,919	59,910	67,854	78,549	88,983	97,675	103,891	109,550	113,760	46,683	54,649
Return on total capital		4.38%	-0.12%	-2.13%	-4.46%	-6.03%	-2.36%	-9.61%	-12.78%	-14.60%	-48.79%	-44.40%	-38.26%	-29.92%	-21.70%	-18.78%	-19.04%	-20.25%	-21.47%	-39.11%	-33.34%

September 30, 2024 calculation

Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $31,455K ÷ ($508,531K + $209,920K)
= 4.38%

TransMedics Group Inc's return on total capital has displayed significant variability over the past few years, with the figure ranging from positive to negative values. The return on total capital was positive at 4.38% as of September 30, 2024, indicating that the company generated a return on its total capital invested. However, in the previous quarter, the return on total capital was negative at -0.12%.

Looking further back, the return on total capital has generally been negative, with the lowest point recorded at -48.79% as of June 30, 2022. This indicates that the company struggled to generate sufficient returns on the total capital employed during that period.

Overall, TransMedics Group Inc's return on total capital has been quite volatile, reflecting fluctuations in the profitability and efficiency of the company's capital utilization. Investors and stakeholders may closely monitor these figures to assess the company's ability to generate returns on its total capital and its overall financial health.